Neurolixis Inc. has in-licensed two clinical phase compounds from Pierre Fabre Médicament. The compounds, NLX-112 (also known as befiradol or F13640, Phase II) and NLX-101 (also known as F15599, Phase I), are highly selective serotonergic 5-HT1A receptor agonists and will be developed by Neurolixis for the treatment of L-DOPA-induced dyskinesia and for breathing deficits in Rett syndrome, respectively. These serious neurological disorders represent large unmet medical needs and substantial market opportunities.

Read the full press announcement:  pdf_symbol.


Please enable the javascript to submit this form

Follow Neurolixis on: